Statera Biopharma

STAB · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0001

Latest news

  • Press releaseBusiness Wire

    Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.